Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Mar
12
Today In Oncology
Structured Exercise Plan for Patients With Cancer May Reduce Cognitive Effects of Chemotherapy
Risk of Breast Cancer After Ovarian Cancer in Women With BRCA1/2 Variants
Metastatic Uveal Melanoma Nivoluma and Ipilimumab Plus Percutaneous Hepatic Perfusion
FDA Releases Updated Guidance on Biosimilar Development
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo